エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2025
Commission File Number: 001-41923
Eupraxia Pharmaceuticals Inc.
(Translation of registrant’s name into English)
201-2067 Cadboro Bay Road
Victoria, British Columbia, Canada V8R 5G4
Telephone : (250) 590-3968
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☐ Form 40-F ☒
DOCUMENTS INCLUDED AS PART OF THIS REPORT
| Exhibit |
||
| 99.1 | Material Change Report of the Registrant, dated February 20, 2025 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Eupraxia Pharmaceuticals Inc.. | |||
| (Registrant) | ||||
| Date: September 19, 2025 | /s/ Alex Rothwell | |||
| Alex Rothwell | ||||
| Chief Financial Officer | ||||
Exhibit 99.1
FORM 51-102F3
MATERIAL CHANGE REPORT
| Item 1: | Name and Address of Company |
Eupraxia Pharmaceuticals Inc. (the “Company”)
201-2067 Cadboro Bay Rd.
Victoria, British Columbia
Canada, V8R 5G4
| Item 2: | Date of Material Change |
February 18, 2025
| Item 3: | News Release |
A news release announcing the material change was issued on February 18, 2025 through Globe Newswire and a copy was subsequently filed on SEDAR+.
| Item 4: | Summary of Material Change |
On February 18, 2025, the Company announced that it had appointed Alex Rothwell as the Company’s new Chief Financial Officer (“CFO”), effective immediately.
| Item 5.1: | Full Description of Material Change |
On February 18, 2025, the Company announced that it had appointed Alex Rothwell as the Company’s new CFO, effective immediately.
Bruce Cousins, the Company’s outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities.
| Item 5.2: | Disclosure of Restructuring Transactions |
Not applicable.
| Item 6: | Reliance on subsection 7.1(2) of National Instrument 51-102 |
Not applicable.
| Item 7: | Omitted Information |
Not applicable.
| Item 8: | Executive Officer |
For further information, please contact James A. Helliwell, Chief Executive Officer of the Company at 250-590-3968.
| Item 9: | Date of Report |
February 20, 2025